Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) have been assigned an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $6.6667.

IPHA has been the topic of a number of analyst reports. UBS Group reiterated a “buy” rating on shares of Innate Pharma in a research note on Tuesday, August 11th. Weiss Ratings upgraded shares of Innate Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, June 26th. Leerink Partners upgraded shares of Innate Pharma from a “market perform” rating to an “outperform” rating and set a $4.00 price target for the company in a research note on Tuesday, August 11th. HC Wainwright boosted their price objective on shares of Innate Pharma from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Monday, August 10th. Finally, BTIG Research upped their target price on shares of Innate Pharma from $8.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, August 12th.

Institutional Trading of Innate Pharma

Several institutional investors and hedge funds have recently bought and sold shares of IPHA. OLD Mission Capital LLC acquired a new position in shares of Innate Pharma during the 4th quarter worth approximately $50,000. Jane Street Group LLC acquired a new stake in Innate Pharma during the 4th quarter valued at $162,000. Finally, Millennium Management LLC acquired a new stake in Innate Pharma during the 4th quarter valued at $36,000. Institutional investors own 0.16% of the company’s stock.

Innate Pharma Trading Up 3.7%

IPHA opened at $2.26 on Tuesday. The business’s 50-day simple moving average is $1.85 and its 200 day simple moving average is $1.69. Innate Pharma has a 52-week low of $1.17 and a 52-week high of $2.71.

About Innate Pharma

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.